Ascorbic acid in Charcot–Marie–Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial
Open Access
- 30 April 2011
- journal article
- research article
- Published by Elsevier BV in The Lancet Neurology
- Vol. 10 (4), 320-328
- https://doi.org/10.1016/s1474-4422(11)70025-4
Abstract
No abstract availableKeywords
Funding Information
- Telethon-UILDM (GUP04002, GUP05007)
- AIFA (Italian Medicines Agency (FARM53APAH)
- the Muscular Dystrophy Campaign in the UK (RA3/736/1)
This publication has 24 references indexed in Scilit:
- 168th ENMC International Workshop: Outcome measures and clinical trials in Charcot–Marie–Tooth disease (CMT)Neuromuscular Disorders, 2010
- Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trialBMC Medicine, 2009
- Diagnosis, natural history, and management of Charcot–Marie–Tooth diseaseThe Lancet Neurology, 2009
- Reliability of clinical outcome measures in Charcot-Marie-Tooth diseaseNeuromuscular Disorders, 2008
- Neuropathy progression in Charcot-Marie-Tooth disease type 1ANeurology, 2008
- Ascorbic acid inhibits PMP22 expression by reducing cAMP levelsNeuromuscular Disorders, 2007
- A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): The study protocol [EudraCT no.: 2006-000032-27]Pharmacological Research, 2006
- A modified peripheral neuropathy scale: the Overall Neuropathy Limitations ScaleJournal of Neurology, Neurosurgery & Psychiatry, 2006
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scalePain, 1983